{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T02:12:26Z","timestamp":1784859146777,"version":"3.55.0"},"reference-count":100,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,4]],"date-time":"2022-11-04T00:00:00Z","timestamp":1667520000000},"content-version":"vor","delay-in-days":1737,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1111\/jth.13913","type":"journal-article","created":{"date-parts":[[2018,1,9]],"date-time":"2018-01-09T22:35:26Z","timestamp":1515537326000},"page":"196-208","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":44,"title":["Anticoagulant prophylaxis and therapy in children: current challenges and emerging issues"],"prefix":"10.1016","volume":"16","author":[{"given":"F.","family":"Newall","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Branchford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Male","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1111\/jth.13913_bb0010","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1542\/peds.2009-0768","article-title":"Dramatic increase in venous thromboembolism in children's hospitals in the United States from 2001 to 2007","volume":"124","author":"Raffini","year":"2009","journal-title":"Pediatrics"},{"key":"10.1111\/jth.13913_bb0015","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1111\/j.1365-2141.2008.07243.x","article-title":"Clinical features and outcome of pulmonary embolism in children","volume":"142","author":"Biss","year":"2008","journal-title":"Br J Haematol"},{"key":"10.1111\/jth.13913_bb0020","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1378\/chest.129.1.174","article-title":"Grading strength of recommendations and quality of evidence in clinical guidelines: report from an American College of Chest Physicians Task Force","volume":"129","author":"Guyatt","year":"2006","journal-title":"Chest"},{"key":"10.1111\/jth.13913_bb0025","first-page":"1045","article-title":"Hospital\u2010associated venous thromboembolism in pediatrics: a systematic review and meta\u2010analysis of risk factors and risk\u2010assessment models","volume":"100","author":"Mahajerin","year":"2015","journal-title":"Haematologica"},{"key":"10.1111\/jth.13913_bb0030","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.jpeds.2014.05.053","article-title":"Development of a new risk score for hospital\u2010associated venous thromboembolism in noncritically ill children: findings from a large single\u2010institutional case\u2010control study","volume":"165","author":"Atchison","year":"2014","journal-title":"J Pediatr"},{"key":"10.1111\/jth.13913_bb0035","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/j.thromres.2015.04.036","article-title":"Development of a new risk score for hospital\u2010associated venous thromboembolism in critically\u2010ill children not undergoing cardiothoracic surgery","volume":"136","author":"Arlikar","year":"2015","journal-title":"Thromb Res"},{"key":"10.1111\/jth.13913_bb0040","first-page":"1","article-title":"Risk factors for hospital\u2010associated venous thromboembolism in critically ill children following cardiothoracic surgery or therapeutic cardiac catheterisation","author":"Atchison","year":"2017","journal-title":"Cardiol Young"},{"key":"10.1111\/jth.13913_bb0045","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.thromres.2014.05.036","article-title":"Risk factors for hospital\u2010associated venous thromboembolism in the neonatal intensive care unit","volume":"134","author":"Amankwah","year":"2014","journal-title":"Thromb Res"},{"key":"10.1111\/jth.13913_bb0050","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1160\/TH05-01-0047","article-title":"Developmental haemostasis. Impact for clinical haemostasis laboratories","volume":"95","author":"Monagle","year":"2006","journal-title":"Thromb Haemost"},{"key":"10.1111\/jth.13913_bb0055","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.419.419","article-title":"Determining the incidence and risk factors for central venous catheter\u2010related thrombosis in children","volume":"128","author":"Jaffray","year":"2016","journal-title":"Blood"},{"key":"10.1111\/jth.13913_bb0060","unstructured":"US National Institutes of Health. ClinicalTrials.gov. Available at: https:\/\/clinicaltrials.gov\/ct2\/home (accessed accessed 01 September 2017)."},{"key":"10.1111\/jth.13913_bb0065","doi-asserted-by":"crossref","first-page":"e278S","DOI":"10.1378\/chest.11-2404","article-title":"Prevention of VTE in orthopedic surgery patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence\u2010Based Clinical Practice Guidelines","volume":"141","author":"Falck\u2010Ytter","year":"2012","journal-title":"Chest"},{"key":"10.1111\/jth.13913_bb0070","doi-asserted-by":"crossref","first-page":"e227S","DOI":"10.1378\/chest.11-2297","article-title":"Prevention of VTE in nonorthopedic surgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence\u2010Based Clinical Practice Guidelines","volume":"141","author":"Gould","year":"2012","journal-title":"Chest"},{"key":"10.1111\/jth.13913_bb0075","doi-asserted-by":"crossref","first-page":"e195S","DOI":"10.1378\/chest.11-2296","article-title":"Prevention of VTE in nonsurgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence\u2010Based Clinical Practice Guidelines","volume":"141","author":"Kahn","year":"2012","journal-title":"Chest"},{"key":"10.1111\/jth.13913_bb0080","doi-asserted-by":"crossref","first-page":"e1326","DOI":"10.1542\/peds.2010-3282","article-title":"Thromboprophylaxis in a pediatric hospital: a patient\u2010safety and quality\u2010improvement initiative","volume":"127","author":"Raffini","year":"2011","journal-title":"Pediatrics"},{"key":"10.1111\/jth.13913_bb0085","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1111\/jth.12773","article-title":"Central venous catheter\u2010related thrombosis and thromboprophylaxis in children: a systematic review and meta\u2010analysis: reply","volume":"13","author":"Vidal","year":"2015","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.13913_bb0090","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.thromres.2017.07.002","article-title":"Epidemiology, diagnosis, prevention and treatment of catheter\u2010related thrombosis in children and adults","volume":"157","author":"Baumann Kreuziger","year":"2017","journal-title":"Thromb Res"},{"key":"10.1111\/jth.13913_bb0095","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.1111\/jth.13848","article-title":"Recommendations for standardized risk factor definitions in pediatric hospital\u2010acquired venous thromboemebolism (HA\u2010VTE) to inform future prevention trials: communication from the SSC of the ISTH","volume":"15","author":"Branchford","year":"2017","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.13913_bb0100","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1097\/SLA.0b013e3181b5d61c","article-title":"Intermittent pneumatic compression or graduated compression stockings for deep vein thrombosis prophylaxis? A systematic review of direct clinical comparisons","volume":"251","author":"Morris","year":"2010","journal-title":"Ann Surg"},{"key":"10.1111\/jth.13913_bb0105","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1161\/CIRCULATIONAHA.113.002690","article-title":"Stratified meta\u2010analysis of intermittent pneumatic compression of the lower limbs to prevent venous thromboembolism in hospitalized patients","volume":"128","author":"Ho","year":"2013","journal-title":"Circulation"},{"key":"10.1111\/jth.13913_bb0110","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1097\/00000658-199709000-00010","article-title":"The fibrinolytic effects of intermittent pneumatic compression: mechanism of enhanced fibrinolysis","volume":"226","author":"Comerota","year":"1997","journal-title":"Ann Surg"},{"key":"10.1111\/jth.13913_bb0115","doi-asserted-by":"crossref","first-page":"e737S","DOI":"10.1378\/chest.11-2308","article-title":"Antithrombotic therapy in neonates and children: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence\u2010Based Clinical Practice Guidelines","volume":"141","author":"Monagle","year":"2012","journal-title":"Chest"},{"key":"10.1111\/jth.13913_bb0120","first-page":"CD012185","article-title":"Heparin for the treatment of thrombosis in neonates","volume":"11","author":"Romantsik","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1111\/jth.13913_bb0125","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1111\/j.1538-7836.2011.04539.x","article-title":"Incidence of thrombotic and bleeding complications during cardiac catheterization in children: comparison of high\u2010dose vs. low\u2010dose heparin protocols","volume":"9","author":"Hanslik","year":"2011","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.13913_bb0130","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1182\/blood-2015-06-651661","article-title":"Monitoring unfractionated heparin in children: a parallel\u2010cohort randomized controlled trial comparing 2 dose protocols","volume":"126","author":"Hanslik","year":"2015","journal-title":"Blood"},{"key":"10.1111\/jth.13913_bb0135","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/jth.13539","article-title":"Anti\u2010activated factor\u00a0II assay for monitoring unfractionated heparin in children: results of the HEARTCAT study","volume":"15","author":"Hanslik","year":"2017","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.13913_bb0140","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1111\/bcp.12930","article-title":"Development of a population pharmacokinetic\u2013pharmacodynamic model of a single bolus dose of unfractionated heparin in paediatric patients","volume":"82","author":"Al\u2010Sallami","year":"2016","journal-title":"Br J Clin Pharmacol"},{"key":"10.1111\/jth.13913_bb0145","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1111\/j.1365-2141.2010.08302.x","article-title":"Clinical use of unfractionated heparin therapy in children: time for change?","volume":"150","author":"Newall","year":"2010","journal-title":"Br J Haematol"},{"key":"10.1111\/jth.13913_bb0150","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1177\/0218492311434646","article-title":"Assessment of the standard pediatric unfractionated heparin dosing protocol","volume":"20","author":"Al Obary","year":"2012","journal-title":"Asian Cardiovasc Thorac Ann"},{"key":"10.1111\/jth.13913_bb0155","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1203\/00006450-199401000-00016","article-title":"Heparin therapy in pediatric patients: a prospective cohort study","volume":"35","author":"Andrew","year":"1994","journal-title":"Pediatr Res"},{"key":"10.1111\/jth.13913_bb0160","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1111\/j.1538-7836.2012.04624.x","article-title":"Unfractionated heparin dosing in young infants: clinical outcomes in a cohort monitored with anti\u2010factor\u00a0Xa levels","volume":"10","author":"Schechter","year":"2012","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.13913_bb0165","doi-asserted-by":"crossref","first-page":"e340","DOI":"10.1097\/PCC.0000000000000174","article-title":"Antithrombin concentrate in pediatric patients requiring unfractionated heparin anticoagulation: a retrospective cohort study","volume":"15","author":"Ryerson","year":"2014","journal-title":"Pediatr Crit Care Med"},{"key":"10.1111\/jth.13913_bb0170","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.thromres.2012.11.012","article-title":"Latent antithrombin levels in children and adults","volume":"131","author":"Karlaftis","year":"2013","journal-title":"Thromb Res"},{"key":"10.1111\/jth.13913_bb0175","doi-asserted-by":"crossref","first-page":"554","DOI":"10.3324\/haematol.10696","article-title":"Lack of correlation between heparin dose and standard clinical monitoring tests in treatment with unfractionated heparin in critically ill children","volume":"92","author":"Kuhle","year":"2007","journal-title":"Haematologica"},{"key":"10.1111\/jth.13913_bb0180","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1160\/TH09-09-0624","article-title":"Age is a determinant factor for measures of concentration and effect in children requiring unfractionated heparin","volume":"103","author":"Newall","year":"2010","journal-title":"Thromb Haemost"},{"key":"10.1111\/jth.13913_bb0185","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.thromres.2007.09.007","article-title":"Utility of aPTT in monitoring unfractionated heparin in children","volume":"122","author":"Chan","year":"2008","journal-title":"Thromb Res"},{"key":"10.1111\/jth.13913_bb0190","first-page":"1085","article-title":"Experience with intravenous enoxaparin in critically ill infants and children","volume":"103","author":"Crary","year":"2010","journal-title":"Thromb Haemost"},{"key":"10.1111\/jth.13913_bb0195","doi-asserted-by":"crossref","first-page":"e207","DOI":"10.1097\/PCC.0000000000001126","article-title":"IV versus subcutaneous enoxaparin in critically ill infants and children: comparison of dosing, anticoagulation quality, efficacy, and safety outcomes","volume":"18","author":"Diab","year":"2017","journal-title":"Pediatr Crit Care Med"},{"key":"10.1111\/jth.13913_bb0200","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1111\/j.1538-7836.2010.03964.x","article-title":"Population pharmacokinetics of enoxaparin in infants, children and adolescents during secondary thromboembolic prophylaxis: a cohort study","volume":"8","author":"Trame","year":"2010","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.13913_bb0205","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1017\/S1047951109990564","article-title":"Do neonates, infants and young children need a higher dose of enoxaparin in the cardiac intensive care unit?","volume":"20","author":"de Toledo","year":"2010","journal-title":"Cardiol Young"},{"key":"10.1111\/jth.13913_bb0210","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1038\/jp.2015.84","article-title":"Feasibility and safety of enoxaparin whole milligram dosing in premature and term neonates","volume":"35","author":"Goldsmith","year":"2015","journal-title":"J Perinatol"},{"key":"10.1111\/jth.13913_bb0215","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1111\/j.1365-2141.2010.08163.x","article-title":"Dosing and monitoring of enoxaparin (low molecular weight heparin) therapy in children","volume":"149","author":"Ignjatovic","year":"2010","journal-title":"Br J Haematol"},{"key":"10.1111\/jth.13913_bb0220","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1097\/PCC.0000000000000640","article-title":"Higher tinzaparin dosing is needed to achieve target anti\u2010xa levels in pediatric cardiac intensive care patients","volume":"17","author":"Roeleveld","year":"2016","journal-title":"Pediatr Crit Care Med"},{"key":"10.1111\/jth.13913_bb0225","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1097\/MPH.0b013e31816356f8","article-title":"Nadroparin therapy in pediatric patients with venous thromboembolic disease","volume":"30","author":"van Ommen","year":"2008","journal-title":"J Pediatr Hematol Oncol"},{"key":"10.1111\/jth.13913_bb0230","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1097\/MBC.0b013e32835b72b8","article-title":"Dosing and monitoring of enoxaparin therapy in children: experience in a tertiary care hospital","volume":"24","author":"Andrade\u2010Campos","year":"2013","journal-title":"Blood Coag Fibrinol"},{"key":"10.1111\/jth.13913_bb0235","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1007\/s00134-007-0718-8","article-title":"Enoxaparin therapy for arterial thrombosis in infants with congenital heart disease","volume":"33","author":"Bontadelli","year":"2007","journal-title":"Intensive Care Med"},{"key":"10.1111\/jth.13913_bb0240","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1177\/1076029613480557","article-title":"Evaluation of the use of low\u2010molecular\u2010weight heparin in neonates: a retrospective, single\u2010center study","volume":"19","author":"Chander","year":"2013","journal-title":"Clin Appl Thromb Hemost"},{"key":"10.1111\/jth.13913_bb0245","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1592\/phco.27.9.1263","article-title":"Enoxaparin use in the neonatal intensive care unit: experience over 8\u00a0years","volume":"27","author":"Malowany","year":"2007","journal-title":"Pharmacotherapy"},{"key":"10.1111\/jth.13913_bb0250","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1111\/jth.12641","article-title":"Lack of anti\u2010factor\u00a0Xa assay standardization results in significant low molecular weight heparin (enoxaparin) dose variation in neonates and children","volume":"12","author":"Greene","year":"2014","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.13913_bb0255","first-page":"1","article-title":"A pilot feasibility and safety multicenter trial of administering weight adjusted FIXed dose of low molecular weight heparin (Enoxaparin) to neonates with thrombosis (FIXET): study protocol","volume":"1","author":"Bhatt","year":"2017","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1111\/jth.13913_bb0260","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1002\/pbc.23308","article-title":"Risk factors for elevated INR values during warfarin therapy in hospitalized pediatric patients","volume":"58","author":"Moffett","year":"2012","journal-title":"Pediatr Blood Cancer"},{"key":"10.1111\/jth.13913_bb0265","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1002\/pbc.24546","article-title":"Readmissions for warfarin\u2010related bleeding in pediatric patients after hospital discharge","volume":"60","author":"Moffett","year":"2013","journal-title":"Pediatr Blood Cancer"},{"key":"10.1111\/jth.13913_bb0270","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1093\/ejcts\/ezw159","article-title":"No difference between aspirin and warfarin after extracardiac Fontan in a propensity score analysis of 475 patients","volume":"50","author":"Iyengar","year":"2016","journal-title":"Eur J Cardiothorac Surg"},{"key":"10.1111\/jth.13913_bb0275","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.jacc.2011.01.061","article-title":"A multicenter, randomized trial comparing heparin\/warfarin and acetylsalicylic acid as primary thromboprophylaxis for 2\u00a0years after the Fontan procedure in children","volume":"58","author":"Monagle","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"10.1111\/jth.13913_bb0280","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.jpeds.2017.04.051","article-title":"Safety and efficacy of warfarin therapy in Kawasaki disease","volume":"189","author":"Baker","year":"2017","journal-title":"J Pediatr"},{"key":"10.1111\/jth.13913_bb0285","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1007\/s00246-011-9984-x","article-title":"Management of warfarin in children with heart disease","volume":"32","author":"Mahle","year":"2011","journal-title":"Pediatr Cardiol"},{"key":"10.1111\/jth.13913_bb0290","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.thromres.2014.05.007","article-title":"Anticoagulation of cardiomyopathy in children","volume":"134","author":"Monagle","year":"2014","journal-title":"Thromb Res"},{"key":"10.1111\/jth.13913_bb0295","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.thromres.2011.04.020","article-title":"Safety and efficacy of warfarin in paediatric patients with prosthetic cardiac valves: a retrospective audit","volume":"128","author":"Wong","year":"2011","journal-title":"Thromb Res"},{"key":"10.1111\/jth.13913_bb0300","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.thromres.2013.01.018","article-title":"Commencement of warfarin therapy in children following the Fontan procedure","volume":"131","author":"Crone","year":"2013","journal-title":"Thromb Res"},{"key":"10.1111\/jth.13913_bb0305","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1111\/j.1365-2141.2012.09230.x","article-title":"Warfarin dose prediction in children using pharmacogenetics information","volume":"159","author":"Biss","year":"2012","journal-title":"Br J Haematol"},{"key":"10.1111\/jth.13913_bb0310","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1182\/blood-2011-08-372722","article-title":"VKORC1 and CYP2C9 genotype and patient characteristics explain a large proportion of the variability in warfarin dose requirement among children","volume":"119","author":"Biss","year":"2012","journal-title":"Blood"},{"key":"10.1111\/jth.13913_bb0315","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1038\/tpj.2014.31","article-title":"Pharmacogenetics of warfarin in a paediatric population: time in therapeutic range, initial and stable dosing and adverse effects","volume":"14","author":"Hawcutt","year":"2014","journal-title":"Pharmacogenomics J"},{"key":"10.1111\/jth.13913_bb0320","doi-asserted-by":"crossref","first-page":"132","DOI":"10.2133\/dmpk.DMPK-12-RG-078","article-title":"Influence of CYP4F2 polymorphisms and plasma vitamin\u00a0K levels on warfarin sensitivity in Japanese pediatric patients","volume":"28","author":"Hirai","year":"2013","journal-title":"Drug Metab Pharmacokinet"},{"key":"10.1111\/jth.13913_bb0325","doi-asserted-by":"crossref","first-page":"295","DOI":"10.2133\/dmpk.DMPK-10-NT-082","article-title":"Effect of the VKORC1 genotype on warfarin dose requirements in Japanese pediatric patients","volume":"26","author":"Kato","year":"2011","journal-title":"Drug Metab Pharmacokinet"},{"key":"10.1111\/jth.13913_bb0330","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1182\/blood-2011-07-365502","article-title":"Vitamin\u00a0K antagonists in children with heart disease: height and VKORC1 genotype are the main determinants of the warfarin dose requirement","volume":"119","author":"Moreau","year":"2012","journal-title":"Blood"},{"key":"10.1111\/jth.13913_bb0335","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1007\/s00246-012-0592-1","article-title":"Genetic and clinical determinants influencing warfarin dosing in children with heart disease","volume":"34","author":"Nguyen","year":"2013","journal-title":"Pediatr Cardiol"},{"key":"10.1111\/jth.13913_bb0340","doi-asserted-by":"crossref","first-page":"6101","DOI":"10.1182\/blood-2010-05-283861","article-title":"In pediatric patients, age has more impact on dosing of vitamin\u00a0K antagonists than VKORC1 or CYP2C9 genotypes","volume":"116","author":"Nowak\u2010G\u00f6ttl","year":"2010","journal-title":"Blood"},{"key":"10.1111\/jth.13913_bb0345","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1002\/pbc.24932","article-title":"VKORC1 and CYP2C9 genotypes are predictors of warfarin\u2010related outcomes in children","volume":"61","author":"Shaw","year":"2014","journal-title":"Pediatr Blood Cancer"},{"key":"10.1111\/jth.13913_bb0350","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1111\/bjh.12817","article-title":"The impact of age and CYP2C9 and VKORC1 variants on stable warfarin dose in the paediatric population","volume":"165","author":"Vear","year":"2014","journal-title":"Br J Haematol"},{"key":"10.1111\/jth.13913_bb0355","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s40291-016-0212-5","article-title":"Effect of VKORC1, CYP2C9, CFP4F2, and GGCX gene polymorphisms on warfarin dose in Japanese pediatric patients","volume":"20","author":"Wakamiya","year":"2016","journal-title":"Mol Diagn Ther"},{"key":"10.1111\/jth.13913_bb0360","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/bcp.12308","article-title":"Characterizing variability in warfarin dose requirements in children using modelling and simulation","volume":"78","author":"Hamberg","year":"2014","journal-title":"Br J Clin Pharmacol"},{"key":"10.1111\/jth.13913_bb0365","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.dmpk.2016.03.007","article-title":"A model analysis for dose\u2013response relationship of warfarin in Japanese children: an introduction of the SIZE parameter","volume":"31","author":"Nakamura","year":"2016","journal-title":"Drug Metab Pharmacokinet"},{"key":"10.1111\/jth.13913_bb0370","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1111\/1755-5922.12230","article-title":"Cytochrome P450 2C9 gene polymorphism and warfarin maintenance dosage in pediatric patients: a systematic review and meta\u2010analysis","volume":"35","author":"Zhang","year":"2017","journal-title":"Cardiovasc Ther"},{"key":"10.1111\/jth.13913_bb0375","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/j.thromres.2015.09.018","article-title":"The influence of VKORC1 gene polymorphism on warfarin maintenance dosage in pediatric patients: a systematic review and meta\u2010analysis","volume":"136","author":"Zhang","year":"2015","journal-title":"Thromb Res"},{"key":"10.1111\/jth.13913_bb0380","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1002\/pbc.23396","article-title":"The impact of quality and duration of enoxaparin therapy on recurrent venous thrombosis in children","volume":"59","author":"Estepp","year":"2012","journal-title":"Pediatr Blood Cancer"},{"key":"10.1111\/jth.13913_bb0385","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1111\/jth.13038","article-title":"Multicenter randomized controlled trial on Duration of Therapy for Thrombosis in Children and Young Adults (the Kids\u2010DOTT trial): pilot\/feasibility phase findings","volume":"13","author":"Goldenberg","year":"2015","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.13913_bb0390","unstructured":"European Medicines Agency. Public Assessment Reports. Available at: http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/landing\/epar_search.jsp&mid=WC0b01ac058001d124 (accessed accessed 01 September 2017)."},{"key":"10.1111\/jth.13913_bb0395","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1007\/s40264-016-0464-3","article-title":"Risk\u2010benefit profile of direct\u2010acting oral anticoagulants in established therapeutic indications: an overview of systematic reviews and observational studies","volume":"39","author":"Raschi","year":"2016","journal-title":"Drug Saf"},{"key":"10.1111\/jth.13913_bb0400","unstructured":"US Food and Drug Administration. Pediatric Research Equity Act (PREA) and Best Pharmaceuticals for Children Act (BPCA) 2007. Available at: http:\/\/www.fda.gov\/downloads\/Drugs\/DevelopmentApprovalProcess\/DevelopmentResources\/UCM049870.pdf (accessed 01 September 2017)."},{"key":"10.1111\/jth.13913_bb0405","article-title":"Regulation (EC) Nos 1901\/2006 and 1902\/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use","volume":"18","year":"2006","journal-title":"Official J Eur Communities"},{"key":"10.1111\/jth.13913_bb0410","unstructured":"European Medicines Agency. Opinions and decisions on paediatric investigation plans. Available at: http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/landing\/pip_search.jsp&mid=WC0b01ac058001d129 (accessed 01 September 2017)."},{"key":"10.1111\/jth.13913_bb0415","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1111\/jth.12807","article-title":"Recommendations for the development of new anticoagulant drugs for pediatric use: communication from the SSC of the ISTH","volume":"13","author":"Male","year":"2015","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.13913_bb0420","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s40262-013-0090-5","article-title":"Development of a paediatric population\u2010based model of the pharmacokinetics of rivaroxaban","volume":"53","author":"Willmann","year":"2014","journal-title":"Clin Pharmacokinet"},{"issue":"Suppl 1","key":"10.1111\/jth.13913_bb0425","first-page":"1","article-title":"Safety, efficacy and PK\/PD of rivaroxaban tablets in children\u00a0with VTE. An Einstein Junior Phase\u00a0II evaluation","volume":"1","author":"Monagle","year":"2017","journal-title":"Res Pract Thromb Haemost"},{"issue":"Suppl 1","key":"10.1111\/jth.13913_bb0430","first-page":"1","article-title":"Safety, efficacy and PK\/PD of a rivaroxaban suspension in children with VTE. An Einstein Junior Phase\u00a0II evaluation","volume":"1","author":"Chan","year":"2017","journal-title":"Res Pract Thromb Haemost"},{"issue":"Suppl 1","key":"10.1111\/jth.13913_bb0435","first-page":"1","article-title":"Safety and PK\/PD of a single rivaroxaban administration in\u00a0children. an Einstein Junior Phase\u00a0I evaluation","volume":"1","author":"Male","year":"2017","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1111\/jth.13913_bb0440","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/j.thromres.2012.07.009","article-title":"The in\u00a0vitro anticoagulant effect of rivaroxaban in children","volume":"130","author":"Attard","year":"2012","journal-title":"Thromb Res"},{"key":"10.1111\/jth.13913_bb0445","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1097\/MBC.0000000000000033","article-title":"The in\u2010vitro anticoagulant effect of rivaroxaban in neonates","volume":"25","author":"Attard","year":"2014","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1111\/jth.13913_bb0450","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.thromres.2015.01.017","article-title":"Assessing the anticoagulant effect of dabigatran in children: an in\u00a0vitro study","volume":"135","author":"Dietrich","year":"2015","journal-title":"Thromb Res"},{"key":"10.1111\/jth.13913_bb0455","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1160\/TH16-06-0423","article-title":"Apixaban pharmacodynamic activity in umbilical cord, paediatric, and adult plasma","volume":"117","author":"Yetman","year":"2017","journal-title":"Thromb Haemost"},{"key":"10.1111\/jth.13913_bb0460","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1160\/TH15-04-0275","article-title":"Safety, tolerability and clinical pharmacology of dabigatran etexilate in adolescents. An open\u2010label phase\u00a0IIa study","volume":"116","author":"Halton","year":"2016","journal-title":"Thromb Haemost"},{"issue":"Suppl 1","key":"10.1111\/jth.13913_bb0465","first-page":"1","article-title":"Anticoagulant effects of dabigatran in paediatric patients compared with adults: combined data from three paediatric clinical trials","volume":"1","author":"Maas","year":"2017","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1111\/jth.13913_bb0470","unstructured":"US Food and Drug Administration. Betrixaban approval. 2017. Available at: https:\/\/www.fda.gov\/drugs\/informationondrugs\/approveddrugs\/ucm564422.htm (accessed 01 September 2017)."},{"key":"10.1111\/jth.13913_bb0475","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1056\/NEJMoa1707278","article-title":"Idarucizumab for dabigatran reversal \u2013 full cohort analysis","volume":"377","author":"Pollack","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1111\/jth.13913_bb0480","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1056\/NEJMoa1607887","article-title":"Andexanet\u00a0alfa for acute major bleeding associated with factor\u00a0xa inhibitors","volume":"375","author":"Connolly","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1111\/jth.13913_bb0485","unstructured":"European Medicines Agency. Paediatric anticoagulation therapy expert meeting, 2012\u201311. Available at: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Minutes\/2013\/07\/WC500145395.pdf (accessed 01 September 2017)."},{"key":"10.1111\/jth.13913_bb0490","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1056\/NEJMoa1300615","article-title":"Dabigatran versus warfarin in patients with mechanical heart valves","volume":"369","author":"Eikelboom","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1111\/jth.13913_bb0495","doi-asserted-by":"crossref","first-page":"e002322","DOI":"10.1161\/JAHA.115.002322","article-title":"Dabigatran is less effective than warfarin at attenuating mechanical heart valve\u2010induced thrombin generation","volume":"4","author":"Jaffer","year":"2015","journal-title":"J Am Heart Assoc"},{"key":"10.1111\/jth.13913_bb0500","doi-asserted-by":"crossref","first-page":"e1435","DOI":"10.1542\/peds.2013-1156","article-title":"Anticoagulant treatment with rivaroxaban in severe protein\u00a0S deficiency","volume":"132","author":"Martinelli","year":"2013","journal-title":"Pediatrics"},{"key":"10.1111\/jth.13913_bb0505","doi-asserted-by":"crossref","first-page":"85","DOI":"10.5482\/HAMO-13-06-0033","article-title":"Phamacokinetics of rivaroxaban in adolescents","volume":"34","author":"Beyer\u2010Westendorf","year":"2014","journal-title":"Hamostaseologie"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjth.13913","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783622009369?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783622009369?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/jth.13913\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T03:20:35Z","timestamp":1761535235000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783622009369"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2]]},"references-count":100,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,2]]}},"alternative-id":["S1538783622009369"],"URL":"https:\/\/doi.org\/10.1111\/jth.13913","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2018,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anticoagulant prophylaxis and therapy in children: current challenges and emerging issues","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1111\/jth.13913","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2018 International Society on Thrombosis and Haemostasis. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}